AFT Pharmaceuticals - FDA nod for opioid alternative, upside anticipated
AFT Pharmaceuticals announced FDA approval for Maxigesic IV, an intravenous form of its flagship pain relief prescription medicine. The FDA...
433 Views
AFT Pharmaceuticals - AFTO judgment clears AFT of breach claim
AFT Pharmaceuticals has reported that the Auckland High Court has cleared it of the contractual breach claim filed by PBL Solutions in April 2020,...
451 Views
AFT Pharmaceuticals - Near-term goals in sight with FY23 momentum
AFT Pharmaceuticals reported another strong fiscal year, capping off three consecutive years of double-digit top-line growth. FY23 revenues of...
212 Views
AFT Pharmaceuticals - Maxigesic IV closer to FDA approval
AFT Pharmaceuticals has announced that the US FDA has allocated a Prescription Drug User Fee Act (PDUFA) date for Maxigesic IV, an intravenous form...
148 Views
AFT Pharmaceuticals - Maxigesic international momentum continues
AFT Pharmaceuticals (AFT) has announced that it has signed three additional licensing agreements for Maxigesic IV – with Labatec in Switzerland and...
204 Views